For the first time in three years, there was no observation of a widening gap in the K-shaped economy. The Index continues to track three consumer segments — Thrivers (those with an Index above 80), the Middle (those with an Index between 50 and 79), and Strivers (those with an Index of 49 and below) — each experiencing different financial realities.

"We have closely observed the K-shaped economy since the COVID-19 pandemic. For the last three years, we have watched the gap between the top and the bottom of the 'K' widen, while the middle class shrank. In the second quarter of 2026, that pattern paused," said Emmaline Aliff, Advisory Leader at Equifax. "The Middle grew slightly, while the Striver population shrank and the Thriver population grew. One quarter does not make a trend, but this is the first quarter in some time where we have observed some improvement."

The Economic Divide Paused

Movement across the three Market Pulse Index consumer segments ran in the opposite direction from recent quarters. The top-tier Thrivers grew by 3.2%, the Middle, which represents nearly 70% of the U.S. population, expanded slightly by 0.9%, and the more economically sensitive Strivers contracted by 4.2%, the segment's sharpest drop since the fourth quarter of 2023.

Assets Remain the Clearest Dividing Line  

Assets, not income or credit, defined as savings or other sources of wealth that can be used for pending needs or debt obligations if needed, remain the clearest dividing line between the segments. Nearly 78% of Thrivers are considered Affluent, holding more than $1 million in assets that act as a strong economic shield. On the opposite end of the spectrum, over 97% of Strivers are Mass Market, with less than $100,000 in assets, and none are considered Affluent.

The Middle segment is where wealth is most mixed. About 32.4% of all U.S. consumers are Mass Affluent households, having between $100,000 and $1 million in assets, sitting in the Middle. Within that specific segment, the split between Mass Affluent and Mass Market is close to even at 46.8% and 42.9%, respectively. Households at similar asset levels can sit on either side of the Middle depending on their credit, debt, and income.

Every Generation Improves Across The Board

For the first time since the third quarter of 2025, Market Pulse Index values rose across all age segments, with the share of Strivers falling in all four groups:

- Millennials led the entire population with a 1.0% quarterly gain to an average Index of 58.7, and posted the largest drop in their Striver share at 1.4 points. Millennials still represent the largest generational group among Strivers at 35.7% of that segment.

- Generation Z rose 0.6% to an average Index of 59.3, continuing a pattern of steady career integration and financial growth. Gen Z posted the largest gain in Thrivers of any generation, up 0.7 points.

- Generation X increased 0.8% to an average Index of 60.8 as they continue to balance peak career debt against the cost of essential needs.

- Boomers+ remain the most financially stable segment with an average Index of 64.5. Their asset cushions anchor both the middle and upper tiers: Boomers+ make up 36.6% of the Middle and 47.8% of Thrivers, the largest generational group in each.

Sentiment vs. Reality: Feelings Didn't Match Financial Changes 

Consumer sentiment, as measured by the University of Michigan Survey of Consumers, fell to 49.5 in the second quarter, marking its lowest reading since tracking began. However, this feeling did not match consumers' actual financial status change for the quarter as sentiment continued to fall even though the Market Pulse Index incrementally rose, and late debt payments improved from 2.1% to 1.9%.

Credit Behavior Is Not the Same as Financial Capacity

Additionally, the latest Market Pulse Index data reiterates that consumers' financial position is not the same as a credit score alone. Prime borrowers (scores of 661–780) make up almost exactly the same share of every segment: 30.0% of Strivers, 30.7% of the Middle, and 23.9% of Thrivers.

At the same time, 9.3% of Thrivers hold scores below 660, and 43.5% of Strivers carry prime or super-prime (scores of 781-850) credit. Excellent payment history is widespread across the country, with super-prime representing 38.4% of the entire U.S. population.

What separates Strivers are tight budgets and a lack of assets rather than difficulty meeting credit obligations: 81% of Strivers earn under $65,000 per year, making them highly sensitive to price changes, while nearly 88% of Thrivers earn more than $100,000.

The Equifax Market Pulse Index provides a comprehensive view of U.S. consumer financial health by synthesizing anonymized credit, debt, income, and asset data with VantageScore credit score insights. The Index is designed to capture the combined effects of multiple economic forces rather than focusing on a single variable. Measured on a scale of 1 to 100 — where 100 represents the greatest financial strength — the Index delivers a holistic picture of consumer economic well-being, allowing for precise comparisons across diverse demographics and generations.

The Equifax Market Pulse Index was built using AI and machine learning methods leveraging proprietary Equifax wealth and asset data along with data from the Equifax credit file and VantageScore 4.0 credit scores to provide a comprehensive view of consumer financial health. It distills the credit, debt, income, capacity, and assets of U.S. consumers into one benchmark number to reflect the cumulative index of both positive and negative financial factors. To learn more, read the full Market Pulse Index here.

ABOUT EQUIFAX INC.

At Equifax (NYSE: EFX), we believe knowledge drives progress. As a global data, analytics, and technology company, we play an essential role in the global economy by helping financial institutions, companies, employers, and government agencies make critical decisions with greater confidence. Our unique blend of differentiated data, analytics, and cloud technology drives insights to power decisions to move people forward. Headquartered in Atlanta and supported by nearly 15,000 employees worldwide, Equifax operates or has investments in 24 countries in North America, Central and South America, Europe, and the Asia Pacific region. For more information, visit Equifax.com.

FOR MORE INFORMATION:

Tiffany Smith for Equifax

[email protected]

SOURCE Equifax Inc.

Share this article

TransDigm Completes Acquisition of Prince & Izant

CLEVELAND, Sept. 28, 2026 /PRNewswire/ -- TransDigm Group Incorporated (NYSE: TDG) today announced that it has successfully completed its acquisition of Prince & Izant ("P&I" or "the Company"), formerly a portfolio company of Industrial Growth Partners, for approximately $1.066 billion in cash, including certain tax benefits. TransDigm financed the acquisition of the Company through cash on hand. The acquisition was previously announced on July 27, 2026.

Headquartered in Cleveland, Ohio, Prince & Izant is a leading global designer and manufacturer of highly engineered brazing alloys and specialty metal components used across a range of advanced performance and high cost-of-failure applications. The Company primarily supports the aerospace and defense, aeroderivative turbine, and transportation end markets. Within aerospace and defense, select applications include aircraft engine fuel nozzles and rocket engines. Additionally, but to a lesser degree, the Company also serves the medical and general industrial end markets.

The Company derives the majority of its revenue from the aftermarket and supports a large installed base globally. Prince & Izant's products are highly proprietary in nature and support end customers through the Company's advanced metallurgy, precise chemistry requirements, and deep formulation expertise which are critical to supporting the evolving performance requirements in the markets which it serves.

The Company's products span nearly 10,000 active SKUs, and the majority of P&I's revenue is derived from specialty metals including gold, silver, and platinum alloys.

P&I is now expected to generate approximately $390 million in revenue for the calendar year ending December 31, 2026. The Company has manufacturing locations in Cleveland, Ohio; Tinley Park, Illinois; Franksville, Wisconsin; and Bay Shore, New York. Prince & Izant employs approximately 220 people.

About TransDigm Group

TransDigm Group, through its wholly-owned subsidiaries, is a leading global designer, producer and supplier of highly engineered aircraft components for use on nearly all commercial and military aircraft in service today. Major product offerings, substantially all of which are ultimately provided to end-users in the aerospace industry, include mechanical/electro-mechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, power conditioning devices, specialized AC/DC electric motors and generators, batteries and chargers, engineered latching and locking devices, engineered rods, engineered connectors and elastomer sealing solutions, databus and power controls, cockpit security components and systems, specialized and advanced cockpit displays, engineered audio, radio and antenna systems, specialized lavatory components, seat belts and safety restraints, engineered and customized interior surfaces and related components, advanced sensor products, switches and relay panels, thermal protection and insulation, lighting and control technology, parachutes, high performance hoists, winches and lifting devices, and cargo loading, handling and delivery systems, specialized flight, wind tunnel and jet engine testing services and equipment, electronic components used in the generation, amplification, transmission and reception of microwave signals, and complex testing and instrumentation solutions.

Forward-Looking Statements

All forward-looking statements involve risks and uncertainties that could cause TransDigm Group's actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, TransDigm Group. These risks and uncertainties include but are not limited to: the sensitivity of our business to the number of flight hours that our customers' planes spend aloft and our customers' profitability, both of which are affected by general economic conditions; supply chain constraints; increases in raw material costs, taxes and labor costs that cannot be recovered in product pricing; failure to complete or successfully integrate acquisitions; our indebtedness; current and future geopolitical or other worldwide events, including, without limitation, wars or conflicts and public health crises; cybersecurity threats; risks related to the transition or physical impacts of climate change and other natural disasters or meeting regulatory requirements; our reliance on certain customers; the United States ("U.S.") defense budget and risks associated with being a government supplier including government audits and investigations; failure to maintain government or industry approvals; risks related to changes in laws and regulations, including increases in compliance costs and potential changes in trade policies and tariffs; potential environmental liabilities; liabilities arising in connection with litigation; risks and costs associated with our international sales and operations; and other factors. Further information regarding the important factors that could cause actual results to differ materially from projected results can be found in TransDigm Group's most recent Annual Report on Form 10-K and other reports that TransDigm Group or its subsidiaries have filed with the Securities and Exchange Commission. Except as required by law, TransDigm Group undertakes no obligation to revise or update the forward-looking statements contained in this press release.

Contact:  

Investor Relations 

(216) 706-2945 

[email protected]   

Share this article

- After years of fans reminiscing about the Chipotle margaritas on social media, the brand is resurrecting its original recipe with a five-city "Summon the Spirits Tour" leading up to Boorito

- The tour will bring $6 margaritas to one Chipotle restaurant every weekend in October, with stops in Denver, New York, Dallas, Los Angeles and New Orleans for a good time, not a long time

- The classic Chipotle Margarita features just five real ingredients with no artificial flavors or mixes

NEWPORT BEACH, Calif., Sep 28, 2026 /PRNewswire/ -- Chipotle Mexican Grill (NYSE: CMG) today announced the "Summon the Spirits Tour," a five-city pop-up tour bringing back its fan-favorite margarita for a limited time ahead of Boorito, the brand's annual Halloween tradition. For years, fans have kept the discontinued drink alive online through nostalgic TikToks, throwback photos and requests for its return (see HERE, HERE) with users commenting "those margs were fireee," and "they need to run that back," and "I really grew up in the wrong era."

Every weekend in October, the margarita will rise again at a new Chipotle restaurant, beginning in the brand's founding city of Denver, followed by stops in New York, Dallas and Los Angeles before a Halloweekend finale in New Orleans. Guests 21 and older can enjoy a Chipotle Margarita for just $6, made with five real ingredients: premium tequila, triple sec, citrus juice, agave nectar and a fresh lime wedge.

"Fans never stopped talking about our margaritas after they left the menu, so Halloween felt like the perfect time to revive a Chipotle classic," said Stephanie Perdue, Senior Vice President of Brand Marketing. "For five weekends, we're giving fans the chance to rediscover the iconic Chipotle Margarita, made with just five real ingredients and the same simplicity we bring to our food."

The Summon the Spirits Tour

Each weekend in October, Chipotle will transform areas of select restaurants into limited-time "Summon the Spirits Tour" pop-up experiences, complete with dedicated margarita bars, immersive Halloween décor, interactive moments and opportunities to unlock Chipotle prizes. The $6 margarita will be available at one Chipotle restaurant every Friday and Saturday throughout October. The schedule is as follows:

- Denver, Colorado 

- When: October 2 and October 3 | 3-9 p.m. local time

- Where: 2760 S. Colorado Blvd., Denver, Colorado 80222

- Spirit: Where the Spirit Began. The tour kicks off in Chipotle's founding city, bringing the margarita back to Denver where the brand's story started.

- New York, New York 

- When: October 9 and October 10 | 3-9 p.m. local time

- Where: 185 Montague St., Brooklyn, NY 11201

- Spirit: Spirits in the City. The tour arrives in one of the world's most influential cultural capitals for a weekend of spirited celebration.

- Dallas, Texas

- When: October 16 and October 17 | 3-9 p.m. local time

- Where: 2401 Victory Park Lane, Dallas, TX 75219

- Spirit: Where Spirits Freeze. The tour stops in the birthplace of the world's first frozen margarita machine,1 with Dallas offering a frozen take on the Chipotle Margarita alongside the original.

- Los Angeles, California

- When: October 23 and October 24 | 3-9 p.m. local time

- Where: 7660 W. Sunset Blvd., Los Angeles, CA 90046

- Spirit: Summon the Stars. The tour arrives in Hollywood, where spirits take center stage.

- New Orleans, Louisiana

- When: October 30 and October 31 | 3-9 p.m. local time

- Where: 2801 Magazine St., New Orleans, LA 70115

- Spirit: Where Spirits Never Rest. The tour's Halloweekend finale lands in one of America's most famously haunted cities.

Boorito Returns on October 31

"The Summon the Spirits Tour" will build anticipation throughout October for Chipotle's annual Boorito tradition, which returns on Halloween with an in-restaurant entrée offer. Additional details on this year's Boorito festivities will be announced later in October.

1 – Source: Smithsonian: The Uniquely Texan Origins of the Frozen Margarita

About Chipotle

Chipotle Mexican Grill, Inc. (NYSE: CMG) is cultivating a better world by serving responsibly sourced, classically-cooked, real food with wholesome ingredients without artificial colors, flavors or preservatives. There are over 4,200 restaurants as of June 30, 2026, in the United States, Canada, the United Kingdom, France, Germany, and the Middle East and it is the only restaurant company of its size that owns and operates all its restaurants in the United States, Canada and Europe. With nearly 140,000 employees passionate about providing a great guest experience, Chipotle is a longtime leader and innovator in the food industry. Chipotle is committed to making its food more accessible to everyone while continuing to be a brand with a demonstrated purpose as it leads the way in digital, technology and sustainable business practices. For more information or to place an order online, visit Chipotle.com. 

SOURCE Chipotle Mexican Grill, Inc.

Share this article

During the two-week program, $1 from every freshly baked waffle cone purchased will support grassroots organizations working on civic engagement and democracy-related initiatives in communities across the country. These groups strengthen community participation and help ensure that people have access to information and resources for the midterm elections.. Simply put, Waffle Lotta Good is how Ben & Jerry's turns a waffle cone into an act of civic power.

"Grassroots organizing is the most powerful tool we have against the erosion of democracy," says Ben & Jerry's Social Mission Director, Carleen Pickard. "When customers buy a waffle cone, they are directly funding the community activists who build that power from the ground up; the people knocking on doors, registering voters, and ensuring that everyone has a voice in decisions that affect their lives. That is how democracy wins."

In recent years, the Waffle Lotta Good program has raised awareness and funding supporting progressive organizations such as Migrant Justice and Black Voters Matter. To learn more about Waffle Lotta Good click here. To find a participating Scoop Shop, visit www.benjerry.com.

About Ben & Jerry's

Ben & Jerry's is an aspiring social justice company that believes in a greater calling than simply making and selling the world's best ice cream. The company produces a wide variety of super-premium ice cream and Non-Dairy/vegan desserts using high-quality ingredients and lots of big chunks and swirls. As a Certified B Corp, Ben & Jerry's incorporates its vision of Linked Prosperity into its business practices via values-led sourcing initiatives when purchasing ingredients. Ben & Jerry's is distributed in over 35 countries in supermarkets, grocery stores, convenience stores, franchised Scoop Shops, and via on-demand delivery services. Ben & Jerry's, a Vermont corporation, operates its business on a three-part Mission Statement emphasizing product quality, a fair financial return, and addressing issues of social, racial, and environmental injustice around the globe. For up-to-date information visit benjerry.com. 

SOURCE Ben & Jerry's

Share this article

SuperX (NASDAQ: SUPX) Launches AI Token Platform and AI Apps at Tech Week Singapore 2026

New products extend SuperX's full-stack capabilities from AI infrastructure into model access and AI application workflows

SINGAPORE, Sept. 28, 2026 /PRNewswire/ -- SuperX AI Technology Limited (NASDAQ: SUPX) ("SuperX" or the "Company"), a full-stack AI infrastructure solutions provider, today announced the launch of its AI Token Platform and AI Apps at Tech Week Singapore 2026 at Booth 5-K45 on September 29 and 30, 2026, at the Marina Bay Sands Expo and Convention Centre, 10 Bayfront Avenue, Singapore.

The AI Token Platform provides unified access to third-party AI models through a single interface and is metered in AI inference tokens, the usage-based units of model input and output as defined by each model provider. Together, the two products extend SuperX's full-stack AI strategy from infrastructure delivery to model access and business applications.

"AI infrastructure provides the foundation, but customers also need reliable access to models and practical tools to put the models to work," said Kenny Sng, Chief Technology Officer of SuperX. "By expanding our portfolio with model access and application tools, we help customers accelerate their journey from compute resources to real-world AI applications."

AI Token Platform for Unified Model Access and Intelligent Routing

Organizations using multiple AI models often need to manage separate provider accounts, APIs and integrations. The AI Token Platform is designed to simplify this process by providing unified multi-model access and AI services for businesses, including AI application developers, internet companies and software companies.

- Unified model access: As of the date of this release, and subject to the applicable model provider's terms, the platform provides access to more than 100 AI models from over 10 providers through a single standardized, OpenAI-compatible API and SDK. Customers can access and switch between text, image, video and audio models without building a separate integration for each provider.

- Model evaluation: Model Plaza, the platform's model catalogue and comparison environment, allows users to test and compare models using their own prompts and evaluate outputs based on performance and estimated cost before selecting a model.

- Intelligent routing and service continuity: The same model can be connected through multiple providers. Requests can be routed based on factors such as region, latency, pricing and service availability, with the option to redirect requests when a provider becomes unavailable.

These capabilities give development teams greater flexibility to select and switch models as performance, availability and commercial requirements change.

AI Apps for Professional Content Creation

AI Apps is designed to support professional teams and enterprise customers across a range of content creation workflows. The platform brings different models, creative tools and digital assets into a shared environment for creating and managing image, video and audio content.

- Shared creative workspace: AI Apps allows users to generate, edit and continue developing content without repeatedly moving assets between separate platforms.

- More precise and accessible creation: Annotations, targeted edits, text replacement and asset references give users greater control over generated content. Built-in Skills (pre-configured instruction templates) translate simple instructions into more complete prompts and execution strategies.

- Reusable assets and team workflows: Generated content can be saved, shared and reused across projects, subject to the terms of the model used to generate it. Teams can collaborate on a shared canvas and track the associated model usage costs.

AI Apps extends model capabilities beyond individual prompts and outputs into a more structured environment for professional content production.

Access to the AI Token Platform and AI Apps is subject to customer onboarding and screening procedures and to applicable export control, sanctions and acceptable use requirements.

At Tech Week Singapore 2026, SuperX will demonstrate the new products alongside its AI compute and AI data center solutions. Visitors can explore these capabilities at Booth 5-K45 on September 29 and 30, 2026, at the Marina Bay Sands Expo and Convention Centre, 10 Bayfront Avenue, Singapore.

For more information, visit the AI Token Platform at https://aicloud.superx.sg/model-plaza and AI Apps at https://aicloud.superx.sg/ai-apps

About SuperX AI Technology Limited

SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sg.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms.

Important factors that could cause actual results to differ materially include: our dependence on third-party model providers and on the terms on which they make their models available; the continued availability and licensing of open-weight models; changes in export control, sanctions and other regulatory requirements applicable to AI compute and model services; the absence of an established revenue history for the products described in this press release; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. Statements in this press release regarding the availability, functionality, performance, pricing or customer adoption of the AI Token Platform and AI Apps, and the models and providers supported by them, are forward-looking and subject to change. Product capabilities described in this press release may be modified or discontinued. Forward-looking statements are only predictions and the reader is cautioned not to rely on them. Actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations and Media Contact

SuperX AI Technology Limited

Investor Relations: [email protected]

Website: www.superx.sg

LinkedIn: https://www.linkedin.com/company/superx-ai

Facebook: https://www.facebook.com/people/Super-X-AI-Technology-Limited/61578918040072/

SOURCE SuperX AI Technology Limited

Share this article

HONOR's Middle East Breakthrough: From Smartphone Challenger to 2nd largest smartphone vendor in the Middle East

In a year when smartphone shipments fell almost everywhere across the region, one brand grew by more than a third — building a position that now runs from Riyadh's malls to a factory floor outside Cairo.

KUWAIT CITY, Sept. 28, 2026 /PRNewswire/ -- There is a particular kind of result that tells you more than a good quarter does: growth in a market that is contracting. It strips away the usual explanations. Rising tides, seasonal demand, a category-wide upgrade cycle none of them apply when everyone else is moving backwards.

That is the position HONOR found itself in through 2026. According to Omdia, the Middle East smartphone market declined 13% year on year in the first half. HONOR grew 35%, the only leading brand in the region to grow at all, and moved into second place. The first quarter had already delivered 73% growth.

Understanding how it happened requires looking market by market, because the region behaved very differently depending on where you stood.

Winning the middle, market by market

The commercial engine was the mid-to-high-end. In the $300–500 price band, HONOR took a 24% share in the first quarter of 2026, growth of 130% year over year that put it within striking distance of Samsung in the segment.

Individual products did the work. The HONOR X9d is built around durability and battery life, a proposition that translates unusually well across the region's climate and became a top seller in both Saudi Arabia and the UAE. The HONOR 600 Series delivered double-digit growth in what the company calls the accessible flagship segment.

The UAE: premium proving ground

If Saudi Arabia is where HONOR proves scale, the UAE is increasingly where it proves premium.

The retail build-out has been deliberate. HONOR opened its first UAE Experience Store at Dubai Festival City Mall, followed by Abu Dhabi's first authorised experience store and service centre, then Al Reem Mall, and in January 2026 a store at BurJuman in Dubai.

That framing is the point. The UAE stores are designed to sell the ecosystem — laptops, tablets, wearables, connected devices — to a market with high disposable income, dense mall culture and consumers who will pay for premium when they can touch it first. In a country where the smartphone market itself is barely growing, ecosystem attachment is where the incremental revenue lives.

Saudi Arabia: scale and infrastructure

Saudi Arabia remains the anchor. HONOR is now the number one tablet brand in the Kingdom by market share, its AIoT business has grown more than 500%, and the HONOR Earbuds Clip alone has passed 100,000 units sold locally.

Behind that sits the big investment: a retail footprint growing to 25 HONOR Experience Stores, eleven of them inside shopping malls, supported by a new contact centre and 16 service centres. Service networks generate no headlines and take years to build. They are also what determines whether a consumer trusts a brand with a second purchase, a more expensive purchase, or an entirely new category — and HONOR has signalled that B2B push is coming to the Kingdom.

Saudi Arabia has also become a key stage for HONOR's technology ambitions. At LEAP 2026 in Riyadh, HONOR presented its ALPHA PLAN: From Vision to Reality, with the Robot Phone making its Middle East debut. The showcase brought together HONOR's vision for AI, robotics and intelligent devices, demonstrating its ambition to move beyond conventional smartphones.

LEAP also reinforced Saudi Arabia's role in HONOR's regional strategy, giving the company a major platform to bring its AI device ecosystem vision to one of the region's most important technology markets.

Egypt: from market to manufacturing base

The most structurally significant move, though, is happening in Egypt — and it has attracted the least attention.

HONOR is expanding its facility at 10th of Ramadan industrial city outside Cairo, its first industrial site anywhere outside China, toward an annual capacity of three million smartphones. The 8,000-square-metre site runs five production lines and two surface-mount technology lines.

The factory is not only about Egypt, as it is intended as an export base into Africa and the wider Arab world, lowering logistics costs, sidestepping import barriers and placing supply closer to the markets it serves. In a period defined by supply-chain fragility and component cost inflation, that is a meaningfully different kind of commitment from opening a showroom.

Building the AI Device Ecosystem

HONOR now describes itself as an AI device ecosystem company rather than a smartphone manufacturer, under a strategy it calls the ALPHA PLAN, a progression from intelligent phone, to intelligent ecosystem, to what it terms an intelligent world.

Its most visible proof point is the Robot Phone, which pairs on-device AI with an integrated robotic gimbal so the device can move, track a subject and respond to its surroundings rather than waiting to be instructed, with imaging developed alongside ARRI, a company that has spent more than a century in professional cinema. The wider roadmap extends to AI glasses, robotics and PCs.

The strategic argument is that intelligence is becoming commoditised in software, and the differentiation moves to hardware capable of sustaining it — battery density, thermal management, durability. In a region where heat and dust are operating conditions rather than edge cases, that argument lands more naturally than it might elsewhere.

The bigger story is that HONOR's regional expansion is no longer being driven by smartphones alone. From growing retail and ecosystem presence in Saudi Arabia and the UAE, to manufacturing in Egypt and a broader AI strategy showcased at LEAP, the company is building the infrastructure for its next phase. The question now is how far that momentum can extend as HONOR moves from being a fast-growing smartphone brand to becoming a broader AI device ecosystem across the Middle East and Africa.

SOURCE HONOR

Share this article

Through this commitment, Lilly aims to expand access to its innovative diabetes and obesity medicines to as many people in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries, before 2040

Key highlights:

- Lilly today launched the Lilly Change the Course Commitment, a new global health initiative with a simple, yet ambitious goal: parity in the number of patients treated. This means treating as many people in resource-limited settings, including LMICs1, as in high-income countries.

- As a medicine company and a leader in diabetes care for over a century, Lilly is stepping up to help close a long-standing access gap in prevention, detection, treatment and care of diabetes and obesity.

- As part of the commitment, Lilly will register its innovative diabetes and obesity medicines in LMICs and work with health systems, regulators, global health organizations, NGOs and other collaborators to help more people in resource-limited settings access the medicines and care they need.

- The commitment follows the completion of the Lilly 30x30 global health initiative, which helped expand access to quality healthcare for 40 million people in resource-limited settings in 2025, surpassing its original goal of helping 30 million people annually by 2030 — five years ahead of schedule.

INDIANAPOLIS, Sept. 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching today the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated with Lilly's innovative diabetes and obesity medicines. This means treating as many people with diabetes and obesity in resource-limited settings, including low- and middle-income countries (LMICs), as in high-income countries before 2040. Today, for every 4 people in high-income countries who have access to Lilly's diabetes and obesity medicines, only 1 person in low- and middle-income countries can reach them. To close this gap, Lilly will focus on three pillars: starting from clinical development of medicines, their registration and access pathways and health systems strengthening.

The announcement follows the completion of the Lilly 30x30 global health initiative five years ahead of schedule, which expanded access to quality healthcare for 40 million people in resource-limited settings in 2025 – exceeding its original goal of reaching 30 million people annually by 2030.

Why is Lilly launching a new commitment now?

4 in 5 adults with diabetes and 7 in 10 adults with obesity live in LMICs, 2-4 and prevalence continues to rise. Historically, people in resource-limited settings have waited decades to access innovative medicines, long after their availability in high-income countries. As a result, the therapies capable of changing the trajectory of diabetes and obesity are still not reaching the people who need them. 

For more than a century, Lilly has been developing innovative medicines for people living with diabetes and obesity. As a leader in this field, Lilly aims to ensure that access to medicines keeps pace with scientific innovation.

David A. Ricks, Lilly chair and CEO: "For 150 years, Lilly has addressed some of humanity's most pressing health challenges by turning science into medicines that improve lives. That same commitment to scientific progress has transformed how we understand and treat diabetes and obesity, conditions that affect more than a billion people worldwide. But innovation only matters when it reaches the people who need it. That is why, as a medicine company that puts health above all, we are now going further. With the Lilly Change the Course Commitment, we aim to treat as many people in resource-limited settings as we do in high-income countries with our diabetes and obesity medicines. Innovative medicines like Foundayo (orforglipron), an oral treatment that can be stored at room temperature, will help us distribute and scale access across more LMICs."

How will Lilly close the gap?

Barriers in resource-limited settings extend beyond the availability of treatment and include fragmented health systems, limited healthcare infrastructure and persistent access gaps. To address them, the Lilly Change the Course Commitment is organized around three focus areas:

- Developing medicines for people who need them: Lilly is working to ensure its diabetes and obesity medicines are suitable for people living in resource-limited settings from the earliest stages of clinical development, focusing on clinical trials, medical presentations and cold chain storage.

- Registering and expanding access to medicines to reach people sooner: Lilly intends to register its innovative diabetes and obesity medicines, including GLP-1s, in more low- and middle- income countries, working with regulatory agencies and local health systems to expand access sooner, with a focus on Africa, Latin America and Asia.

- Helping strengthen health systems: Lilly aims to collaborate with global health organizations to help strengthen primary health systems by training community health workers, leveraging technology and digital tools, and improving disease awareness, prevention, diagnosis, and care in resource-limited settings.

Together, these efforts aim to help more people extend their lifespan and enhance their quality of life by managing their diabetes and obesity earlier, reducing long-term complications, and, over time, preventing new cases of diabetes and obesity.

How will Lilly measure and report progress?

Lilly will report progress in treatment reach against the Lilly Change the Course Commitment through its annual Sustainability Report and at key global health forums.

About Foundayo™ (orforglipron) 

Foundayo™ (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems, to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day with no planning around food or drink.2 Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orfoglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.   

INDICATION AND SAFETY SUMMARY WITH WARNINGS

Foundayo™ (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.  

- Foundayo should not be used with other GLP-1 receptor agonist medicines.

- It is not known if Foundayo is safe and effective for use in children.

Warnings — Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

- Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC).

- Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

- Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo.

Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures.

Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 Million

– LNK001, an AND-gated CAR-T therapy targeting CAIX and ENPP3, is being evaluated in a Phase 1 study in advanced clear cell renal cell carcinoma at MD Anderson Cancer Center –

– Jie D'Elia, Ph.D., joins as Chief Executive Officer and Friedrich Graf Finckenstein, M.D., as Chief Medical Officer; co-founder Brian Slingerland becomes Executive Chair –

– Series A financing upsized from $60 million to $90 million to advance a second solid tumor program in colorectal cancer and expand the pipeline –

SOUTH SAN FRANCISCO, Calif. and AUSTIN, Texas, Sept. 28, 2026 /PRNewswire/ -- Link Cell Therapies ("Link"), an oncology cell therapy company utilizing its proprietary logic-gating technology to develop next-generation CAR-T therapeutics for solid tumors and hematologic malignancies, today announced that it has initiated clinical dosing for its lead program, LNK001. The company also announced three additions to its executive leadership team and a $30 million expansion of its Series A financing.

Initiated clinical dosing of LNK001

LNK001 is being evaluated in a Phase 1 study in patients with advanced or metastatic clear cell renal cell carcinoma ("RCC"). Clinical dosing has begun at MD Anderson Cancer Center.

LNK001 requires the co-expression of two antigens, CAIX and ENPP3, which are both highly expressed in most RCC tumors. CAIX has long been among the most attractive targets in RCC, but conventional CAR-T cells directed against it have been limited by on-target, off-tumor toxicity in the biliary epithelium, where CAIX is also expressed. By gating CAR-T activity on both antigens, LNK001 is designed to preserve the antitumor potential of CAIX targeting while sparing the healthy tissue that has constrained single-antigen approaches.

LNK001 is manufactured at CTMC, a joint venture between Resilience and The University of Texas MD Anderson Cancer Center. Additional clinical trial details are available at https://clinicaltrials.gov/study/NCT07564232.

Leadership additions

Jie D'Elia, Ph.D., joins as Chief Executive Officer and a member of the Board of Directors. Dr. D'Elia was previously the CEO of SystImmune, Inc., a clinical-stage biopharmaceutical company focused on developing novel multi-specific antibodies and antibody-drug conjugates ("ADCs"). Before SystImmune, she spent eleven years at Bristol Myers Squibb ("BMS"), most recently as Senior Vice President of Business Development, Oncology, Hematology, and Cell Therapy. During her tenure at BMS, she made a significant impact to BMS's pipeline evolution through multiple strategic partnerships and acquisitions in therapeutic areas ranging from oncology, hematology, cardiovascular, virology, and cell therapy. Prior to BMS, Dr. D'Elia served as the Vice President and Global Head of Business Development at Simcere Pharmaceutical, and held roles at AstraZeneca, Boston Consulting Group and Baxter Healthcare. Over the course of her career, she has led more than $40 billion in strategic partnerships and acquisitions. Dr. D'Elia holds a Ph.D. from the College of Pharmacy at the University of Texas at Austin and an MBA from Columbia Business School.

Brian Slingerland becomes Executive Chair. Brian co-founded Link in 2022 with Robbie Majzner, M.D., and Crystal Mackall, M.D., and has served on the Board of Directors. He previously co-founded and was the CEO of Stemcentrx, a next-generation ADC company that pursued novel targets with limited or no normal tissue expression, including DLL3 and SEZ6, and built the industry's first end-to-end ADC GMP manufacturing facility. Abbvie acquired Stemcentrx in 2016 for $6.2 billion, which at the time was the largest private acquisition of all time in biotechnology. Prior to founding Stemcentrx, Brian was a Founding Partner at Qatalyst Partners and Vice President at Goldman Sachs where he helped companies raise private venture capital, execute IPOs and other financings, advised on mergers and acquisitions, and gained valuable experience working with CEOs at various stages of development. Brian has held other biotechnology CEO roles, including of recently acquired Convergent Genomics, and Everest Detection, and served on the Boards of Directors and provided initial capital to multiple biotech companies including Enliven Therapeutics. Brian is a graduate of Virginia Tech.

Friedrich Graf Finckenstein, M.D., joins as Chief Medical Officer. Dr Graf Finckenstein is a physician-scientist with decades of experience in clinical medicine, cancer research and drug development. Most recently, as Chief Medical Officer of Iovance Biotherapeutics he progressed the clinical portfolio of Tumor Infiltrating Lymphocyte (TIL) therapies across indications and next generation products and contributed to the approval of AMTAGVI® (lifileucel) in the US, Canada and Australia as the first approved cell therapy for a solid tumor. Before Iovance, he was Global Head of Oncology Translational Medicine at Roche Pharma Research and Early Development (pRED) in Basel, Switzerland. Earlier, he held clinical leadership roles at BMS, spanning early through late-stage development, including contributions to the approval of Opdivo® (nivolumab) in lung cancer. He holds a medical degree from the University of Hamburg, is a board-certified pediatrician and has conducted laboratory cancer research at the Ludwig Institute, San Diego Branch, the Children's Hospital Los Angeles and the University of Hamburg.

"From the beginning, our vision has been to translate this breakthrough science into therapies that can make a profound difference for people impacted by cancer," said co-founder Robbie Majzner, M.D., of the Dana-Farber Cancer Institute and Harvard Medical School. "Bringing in leaders with the experience, commitment and passion to advance our technology and execute at scale gives me tremendous confidence that we can realize that vision."

Abraham Bassan, Member of the Link Board of Directors and Partner at Samsara BioCapital, says "We are excited about the strength and depth of the leadership team at Link. Their broad experience and commitment to advancing our science puts the company in an excellent position to develop a new generation of impactful medicines for patients."

Series A expansion to fund pipeline programs

Link's previously announced $60 million Series A financing led by Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., with participation from founding investors Samsara BioCapital and Sheatree Capital, as well as Wing Venture Capital and new investors including BMS, Kyowa Kirin, Sherpa Healthcare Partners, Western Technology Investment and the MD Anderson Cancer Focus Fund, was upsized to $90 million.

The additional capital will support clinical and preclinical development of additional logic gated CAR-T programs. Link's second solid tumor indication is colorectal cancer, where the company intends to begin a first-in-human trial in 2027 using a novel target pair co-expressed in the majority of colorectal tumors but absent from normal healthy tissues. Additional CAR-T programs in solid and hematologic cancers are in earlier development and will be advanced internally or through partnerships.

"Link's logic-gate platform can make CAR-T broadly viable in solid tumors," said Dr. D'Elia. "A targeting approach that reliably distinguishes tumor from healthy tissue is what allows CAR-T to pursue in solid tumors the kind of deep and durable responses it has achieved in hematologic cancers. This financing lets us advance a pipeline built on that approach across additional tumor types."

About Link Cell Therapies

Link Cell Therapies ("Link") is a biotechnology company based in South San Francisco, California, founded in 2022 by Robbie Majzner, M.D., and Crystal Mackall, M.D. at Stanford University, biotech entrepreneur Brian Slingerland, and Samsara BioCapital. Link's proprietary logic-gating technology allows for safe targeting of multiple antigens that are co-expressed selectively on cancer cells, thereby reducing the risk of on-target, off-tumor toxicity. This enables discovery of an entirely new landscape of "clean" target pairs, and supports the development of next-generation CAR-T therapeutics for solid and hematologic cancers. Link's team features industry-leading scientists collaborating with top-tier advisors and life science financial and strategic investors committed to improving outcomes for cancer patients. To learn more, please visit www.linkcelltx.com.

Media Contact

Link Cell Therapies

[email protected]

SOURCE Link Cell Therapies

Share this article

15 Million Americans Live in a County With No General Surgeon

A new study in the Journal of the American College of Surgeons compares, for the first time, the surgeon supply across 12 surgical specialties, county by county, with an interactive data visualization available to the public

Key Takeaways

- A new study from the American College of Surgeons and the UNC Cecil G. Sheps Center maps surgeon supply across 12 surgical specialties and every US county, and a companion interactive tool visualizes the findings.

- Of 3,144 US counties, 951 had no identified surgeon in any of the 12 surgical specialties, and 1,180 counties had no general surgeon, representing 15.1 million people lacking access to surgical care.

- 434 critical access hospitals, the small rural facilities many communities rely on for emergency and inpatient care, are in counties with no identified full-time surgeon.

- Every US hospital referral region had at least one general surgeon, yet 1,180 counties had none, illustrating that the potential designation of federal shortage areas will be critically dependent on the choice of geographic scale.

WASHINGTON, Sept. 28, 2026 /PRNewswire/ -- More than 15 million Americans live in one of the 1,180 US counties with no general surgeon, and 951 counties have no surgeon in any of 12 surgical specialties, according to a new national analysis announced today at the ACS Clinical Congress 2026 in Washington, D.C., and simultaneously published today in the Journal of the American College of Surgeons (JACS).

The study and a companion interactive tool built on the same data, developed by the American College of Surgeons (ACS) and the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill, map surgeons across 12 specialties and all 3,144 US counties from a single data source, allowing direct comparison for the first time. Previous studies examined one specialty at a time, used different data sources, or reported only national and state totals.

The ACS Surgical Workforce Mapping Tool visualizes the study's findings and gives patients, clinicians, and policymakers direct access to county-level data, allowing hospital boards, residency program directors, state legislators, congressional staffers, and patients to look up, compare, and download surgical workforce data for any county, referral region, or metropolitan/micropolitan area in the country.

"For a patient, the question is not how many surgeons the country has; it is whether there is one available where they live," said Thomas C. Tsai, MD, MPH, FACS, Medical Director for Health Policy Research in the ACS Division of Advocacy and Health Policy and a co-author of the study. "National averages can obscure substantial differences from one community to another. This study highlights a need to assess whether our national health workforce and reimbursement policies are supporting the ability of patients to access the right care at the right time and the right place."

The analysis identified 201,394 surgeons practicing in the U.S. as of April 2025, or 59.2 surgeons per 100,000 people, and mapped each of them to the county, hospital referral region, and metropolitan/micropolitan area where they practice.

Study Results

The 951 counties (30%) with no identified surgeon in any of the 12 specialties are home to 9.6 million people. The 1,180 counties (38%) with no general surgeon are home to 15.1 million.

Every one of the country's 306 hospital referral regions had at least one general surgeon, but these regions are large, multi-county areas defined by where patients travel for major surgical care, so the presence of a surgeon somewhere within one does not mean surgical care is close at hand for patients in its rural counties. Overall, surgeon supply across all 12 specialties was 12 times higher in some regions than others, from 20.8 surgeons per 100,000 people in Harlingen, Texas, to 250.4 in Rochester, Minnesota.

Access varied sharply by specialty. Transplant surgery, at 0.3 surgeons per 100,000 people, was absent from 179 of the country's 306 hospital referral regions, and the most specialized fields were consistently the smallest and the most geographically concentrated. Because the study classified all 12 specialties from a single data source using definitions the ACS developed with input from more than a dozen surgical societies, a community can see which specific specialties it lacks rather than a single aggregate surgeon count.

The findings also highlight potential challenges for rural communities. Researchers overlaid surgeon locations with federal facility files and found 475 hospitals and surgical facilities in counties with no identified full-time surgeon. Of those, 434 were critical access hospitals, the small rural facilities many communities depend on for emergency and inpatient care.

"The Surgical Workforce Mapping Tool gives policymakers, health systems, and communities a practical tool to understand their local surgical workforce and identify gaps in access to care," said Erin P. Fraher, PhD, MPP, Director of the Carolina Health Workforce Research Center at the UNC Sheps Center and the study's lead author.

Users can filter by specialty, switch between counties, hospital referral regions, and metropolitan/micropolitan areas, overlay hospitals and ambulatory surgical centers, and download maps for use in reports and presentations.

"Mapping the surgical workforce is the first step to crafting a thoughtful growth strategy," said Patricia L. Turner, MD, MBA, FACS, Executive Director and CEO of the American College of Surgeons. "These data will help guide investments in surgical training and support for surgeons in underserved communities, with the goal of improving patients' access to care."

The authors caution that uneven distribution is not automatically a problem to be corrected. Transplant surgery is concentrated in part because complex procedures are deliberately regionalized to preserve quality, and the most appropriate distribution is unlikely to be the same for every specialty.

Policy Applications

The findings come as federal policymakers consider how to better identify communities with limited access to surgical care. The Ensuring Access to General Surgery Act of 2026 (H.R. 7198) would direct the Health Resources and Services Administration to develop a methodology for identifying general surgery shortage areas that considers surgeon supply and geographic service areas.

The mapping tool could help policymakers and health care leaders identify where workforce interventions may have the greatest impact, including investments in graduate medical education, rural surgical training, and programs designed to attract and retain surgeons in underserved communities.

About the Data

The study and interactive tool use surgeon location data from the April 2025 National Plan and Provider Enumeration System, a federal registry of clinicians with National Provider Identifiers. Facility locations were drawn from Centers for Medicare & Medicaid Services Provider of Services files.

The analysis identifies where surgeons are located but does not measure patient travel time, surgical volume or capacity, or whether individual surgeons practice at specific hospitals. Full methodology, data sources, and study limitations are available in the JACS study.

Access The ACS Surgical Workforce Mapping Tool

The ACS Surgical Workforce Mapping Tool is free and publicly available on the ACS website. Full methodology and data source documentation are available on facs.org. The study is published as an article in press on the JACS website.

Manuscript Citation: Fraher E, Galloway E, Ricketts T, et al. A National Atlas of Surgeon Supply Across Specialties and Geographic Areas. Journal of the American College of Surgeons. 2026. DOI: 10.1097/XCS.0000000000002224

Cite the Tool: American College of Surgeons & Program on Health Workforce Research and Policy (PHWRP), Cecil G. Sheps Center for Health Services Research, UNC-Chapel Hill. (2026). Surgery Workforce Interactive Map. Data from NPPES April 2025 and CMS Provider of Services Q2 2025. facs.org/advocacy/acs-surgical-workforce-mapping-tool.

Note: The ACS Surgical Workforce Mapping Tool reflects surgeon locations as of April 2025 and will be updated as new federal data are released.

About the American College of Surgeons

The American College of Surgeons (ACS) is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for all surgical patients. The ACS is dedicated to the ethical and competent practice of surgery. Its achievements have significantly influenced the course of scientific surgery in America and have established it as an important advocate for all surgical patients. The ACS has approximately 95,000 members and is the largest organization of surgeons in the world. "FACS" designates that a surgeon is a Fellow of the ACS.

Follow the ACS on social media: X | Instagram | YouTube | LinkedIn | Facebook

About the UNC Cecil G. Sheps Center for Health Services Research

The Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill, a pan-university center, undertakes innovative research and program evaluation to understand health care access, costs, delivery, outcomes and value. This research provides the evidence base to improve health through a more effective and efficient health care system. Its Program on Health Workforce Research and Policy studies the supply, distribution, and training of the health workforce. The study was supported by UNC-CH faculty, researchers, and staff Anthony Charles, MD, MPH, Mustafa Abid, MD and Abhi Joshi, MCS.

SOURCE American College of Surgeons

Share this article

TORONTO, Sept. 28, 2026 /PRNewswire/ -- Jaguar Uranium Corp. (NYSE American: JAGU) ("Jaguar" or the "Company") is pleased to announce that it will participate in the ROTH Capital Partners' inaugural Emerging Nuclear Technology Conference on October 1, 2026, in New York City.

Jaguar management will discuss:

- Ongoing exploration progress and recent successes across its wholly owned portfolio of four uranium, rare earth and copper assets across Argentina and Colombia, including brownfield and former mining assets and districts.

- An overview of the Company's exploration strategy, 2027 plans and the significant potential of its South American asset base.

The conference comes at a time of increasing global focus on nuclear energy, energy security and the development of secure and diversified supply chains for uranium and critical minerals.

About Jaguar Uranium

Jaguar Uranium Corp. is a South America-focused uranium exploration company advancing a portfolio of prospective brownfield projects across Argentina and Colombia. In Argentina, Jaguar is advancing the Laguna Salada Project in Chubut Province and the historic Huemul uranium mine in Mendoza Province. Anchored by a former producing mine, a historic uranium district and exploration projects supported by historical drilling, the Company is focused on advancing and expanding uranium opportunities across the region. The Company's Berlin Project in Caldas Province, Colombia is a district-scale, sedimentary-hosted polymetallic system historically reported to host uranium alongside rare earth elements, vanadium, nickel, phosphate, molybdenum, rhenium and zinc. Jaguar completed a $25 million initial public offering on NYSE American in February 2026 and is led by an experienced team with backgrounds in exploration, permitting, project development and mining finance in South America.

Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of applicable U.S. and Canadian securities laws. Forward-looking statements include statements regarding the Company's exploration strategy, 2027 plans, the advancement and potential of its projects and portfolio, and future exploration activities in Argentina and Colombia.

Forward-looking statements are based on assumptions including the availability of financing, personnel, equipment, property access and required permits, the reliability of historical and exploration data, and the Company's ability to execute its plans as currently contemplated.

Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks inherent in mineral exploration and development, the possibility that exploration may not result in economically recoverable mineralization, reliance on historical data, commodity price volatility, financing, permitting, political and regulatory risks, and general economic, market and industry conditions.

Forward-looking statements speak only as of the date of this news release. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements.

SOURCE Jaguar Uranium

Share this article